Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Nikkiso Co., Ltd. ( (JP:6376) ).
Nikkiso Co., Ltd. announced a series of officer appointments and role confirmations effective January 1, 2026, as approved by its Board of Directors. The resolution largely maintains continuity in top management, with President and CEO Koichi Kato and key business heads in the medical, industrial, aerospace, corporate, and R&D units retaining their current positions, while formalizing Executive Officer status for Kazuhiko Sugimoto as head of the Medical Factory at the Kanazawa Plant. The move underscores organizational stability across Nikkiso’s main business segments and reinforces its governance structure as it continues to manage its diversified portfolio, including its U.S.-based cryogenic subsidiary, without signaling major strategic or operational shifts for stakeholders.
The most recent analyst rating on (JP:6376) stock is a Buy with a Yen1766.00 price target. To see the full list of analyst forecasts on Nikkiso Co., Ltd. stock, see the JP:6376 Stock Forecast page.
More about Nikkiso Co., Ltd.
Nikkiso Co., Ltd., listed on the TSE Prime Market (code 6376), operates as a diversified industrial manufacturer with core businesses in medical equipment, industrial systems, aerospace components, and related technologies. The company also manages healthcare and UV-LED businesses, maintains a research and technology institute with a strong focus on quality assurance, and oversees overseas operations including its U.S. cryogenic subsidiary, positioning it as a multifaceted player in both domestic and global industrial and medical markets.
Average Trading Volume: 242,734
Technical Sentiment Signal: Buy
Current Market Cap: Yen96.64B
See more data about 6376 stock on TipRanks’ Stock Analysis page.